Stock Traders Purchase High Volume of Put Options on Climb Bio (NASDAQ:CLYM)

Climb Bio, Inc. (NASDAQ:CLYM) was the target of unusually large options trading on Thursday. Investors purchased 7,091 put options on the stock. This represents an increase of 1,046% compared to the average daily volume of 619 put options.

Climb Bio Trading Down 4.4%

Climb Bio stock traded down $0.70 during trading hours on Thursday, reaching $15.38. 643,333 shares of the company were exchanged, compared to its average volume of 943,351. Climb Bio has a 12 month low of $1.54 and a 12 month high of $18.33. The stock has a 50-day moving average of $13.69 and a 200 day moving average of $10.37. The firm has a market cap of $883.25 million, a price-to-earnings ratio of -18.53 and a beta of 0.08.

Climb Bio (NASDAQ:CLYM) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.03. As a group, research analysts forecast that Climb Bio will post -0.82 EPS for the current year.

Climb Bio News Summary

Here are the key news stories impacting Climb Bio this week:

• Positive Sentiment: Climb Bio’s Phase 2 trial in China is advancing, providing continued progress for the company’s clinical pipeline. However, investors are also assessing whether that progress is already reflected in the valuation. Climb Bio (CLYM) Advances Phase 2 Trial In China, Is The Valuation Already Priced In?
• Positive Sentiment: HC Wainwright raised its Climb Bio loss estimates across several periods, implying better-than-previously-expected results: FY2026 EPS to $(0.76) from $(0.93), Q3 2026 to $(0.20) from $(0.23), Q4 2026 to $(0.19) from $(0.22), and FY2027 to $(0.98) from $(0.99). The firm reiterated its Buy rating and $24 price target, well above the recent trading level.
• Neutral Sentiment: Short interest was reported at zero shares as of August 25, unchanged from August 10. This indicates no measurable short-selling pressure, although the data provides little additional directional information.
• Neutral Sentiment: Unusually heavy call-option activity occurred Wednesday, with 3,024 calls traded versus typical volume of 360. The activity may reflect bullish speculation, but options volume alone does not confirm that traders expect a sustained advance.
• Negative Sentiment: Put-option activity surged Thursday to 7,091 contracts, approximately 1,046% above the average daily volume of 619. The sharp increase points to heightened hedging or bearish speculation and is the clearest near-term negative market signal.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CLYM. AQR Capital Management LLC bought a new stake in Climb Bio during the first quarter valued at about $27,000. Goldman Sachs Group Inc. bought a new position in shares of Climb Bio in the first quarter worth about $147,000. Marshall Wace LLP acquired a new position in shares of Climb Bio during the 2nd quarter worth about $46,000. Qube Research & Technologies Ltd acquired a new stake in Climb Bio in the 2nd quarter valued at approximately $43,000. Finally, Jane Street Group LLC bought a new position in Climb Bio in the 2nd quarter worth approximately $184,000. Institutional investors and hedge funds own 69.76% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. BTIG Research upped their target price on Climb Bio from $19.00 to $20.00 and gave the stock a “buy” rating in a research report on Thursday, June 11th. Chardan Capital initiated coverage on Climb Bio in a research note on Tuesday, May 5th. They issued a “buy” rating and a $22.00 price target for the company. Truist Financial increased their price objective on Climb Bio from $17.00 to $25.00 and gave the stock a “buy” rating in a report on Friday, August 7th. Royal Bank Of Canada began coverage on shares of Climb Bio in a research report on Monday, August 3rd. They set an “outperform” rating and a $23.00 price objective on the stock. Finally, Wedbush reiterated an “outperform” rating and issued a $20.00 target price on shares of Climb Bio in a research note on Wednesday, August 19th. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $23.08.

Climb Bio Company Profile

Climb Bio Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered protein therapeutics for the treatment of cancer and immune-mediated disorders. The company’s mission centers on designing biologics with enhanced specificity and functional activity to engage key cellular targets and improve patient outcomes in areas of high unmet need.

At the heart of Climb Bio’s approach is its proprietary protein engineering platform, which combines mammalian cell display, directed evolution and computational modeling.